ElectRx causes introduction of unapproved and misbranded prescription drugs into interstate commerce by substituting foreign-sourced drugs for FDA-approved prescriptions.
What happened
FDA observed from ElectRx’s described business model, invoices, and formularies that ElectRx acts as a broker between foreign pharmacies and employer-sponsored health plans. ElectRx accepts U.S. prescriptions and has a foreign pharmacy ship drugs directly to employees, while telling recipients the medications are sourced internationally and may have different names or strengths than U.S. products. FDA says this design substitutes FDA-approved prescription drugs with unapproved and misbranded drugs.
What FDA found
ElectRx caused unapproved new drugs to be introduced into interstate commerce even though no FDA-approved applications were in effect for them.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]ElectRx caused misbranded drugs to be introduced into interstate commerce because the foreign prescription drugs lacked adequate directions for use and no exemption applied.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5, 201.100, 201.115(a)ElectRx substitutes FDA-approved prescription drugs with foreign-sourced versions, such as Advagraf tacrolimus extended-release, which has no FDA-approved application and is an NTI drug with a boxed warning.
FD&C Act § 505(a) [21 U.S.C. § 355(a)]ElectRx’s invoices and formularies state that medications are sourced internationally and may have different names or strengths than U.S. drugs, showing the business is designed to substitute unapproved drugs.
FD&C Act §§ 301(a), 301(d) [21 U.S.C. §§ 331(a), 331(d)]
What FDA wants
FDA asks ElectRx to promptly cease causing the distribution of unapproved new drugs and misbranded drugs to U.S. consumers. ElectRx must notify FDA in writing within 15 working days describing steps taken or planned to correct violations and prevent recurrence, including documentation, or explain why it cannot complete the actions within that time and give a completion timeline.
Who should pay attention
- employers and health plans that use ElectRx as a prescription broker
- patients receiving specialty or maintenance drugs through employer plans
- pharmacies and benefit managers handling foreign-sourced prescriptions
This is a summary. Read the original letter on fda.gov.